EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function

Kyrie Pappas, Matteo Ferrari, Perianne Smith, Subhiksha Nandakumar, Zahra Khan, Serina B Young, Justin LaClair, Marco Vincenzo Russo, Emmet Huang-Hobbs, Nikolaus Schultz, Wassim Abida, Wouter Karthaus und 2 weitere

Proceedings of the National Academy of Sciences · 10.06.2025 · 122 (23)

DOI: 10.1073/pnas.2426743122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.06.2025. Verfasst von Kyrie Pappas und 13 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, BRCA2 Protein. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH (NIH), NCI NIH HHS, HHMI (HHMI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent approvals of polymeric adenosine diphosphate ribose (poly(ADP-ribose) polymerase inhibitors (PARPi) for BRCA-mutant metastatic castration resistant prostate cancer necessitate an understanding of the factors that shape sensitivity and resistance. Reversion mutations that restore homologous recombination (HR) repair are detected in ~50 to 80% of BRCA-mutant patients who respond but subsequently relapse, but there is currently little insight into why only ~50% of BRCA-mutant patients display upfront resistance. To address this question, we performed a genome-wide CRISPR screen to identify genomic determinants of PARPi resistance in murine Brca2 Δ/Δ prostate organoids genetically engineered in a manner that precludes the development of reversion mutations. Remarkably, we recovered multiple independent single guide RNAs (sgRNAs) targeting three different members ( Cdt1, Cdc6, and Dbf4 ) of the DNA prereplication complex (pre-RC), each of which independently conferred resistance to olaparib and the next-generation PARP-1 selective inhibitor AZD5305. Moreover, sensitivity to PARP inhibition was restored in Brca2 Δ/Δ , Cdc6-depleted prostate cells by knockdown of geminin, a negative regulator of Cdt1, further implicating the critical role of a functional pre-RC complex in PARPi sensitivity. Furthermore, ~50% of CRPC tumors have copy number loss of pre-RC complex genes, particularly CDT1 . Mechanistically, prostate cells with impaired pre-RC activity displayed rapid resolution of olaparib-induced DNA damage as well as protection from replication fork degradation caused by Brca2 loss, providing insight into how Brca2-mutant cancer cells can escape cell death from replication stress induced by PARP inhibition in the absence of HR repair. Of note, a pharmacologic inhibitor that targets the CDT1/geminin complex (AF615) restored sensitivity to AZD5305, providing a potential translational avenue to enhance sensitivity to PARP inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmBRCA2 ProteinAnimalsMaleMicePhthalazinesHumansPiperazinesMutationCell Cycle ProteinsDNA ReplicationProstatic Neoplasms, Castration-Resistant

Stichwörter der Autor:innen

CDT1PARPgemininhomologous recombinationprostate

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA2 ProteinolaparibPhthalazinesPiperazinesCell Cycle ProteinsBRCA2 protein, mouse

Autor:innen und Institutionen

  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Department of Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN 55455.
  • Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • The Halvorsen Center for Computational Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
  • Department of Neurosurgery, Columbia University Irving Medical Center, New York, NY 10032.

ORCID-Profile: Maria Jasin, Charles L Sawyers

Förderung

  • HHS | NIH (NIH)
  • NCI NIH HHS
  • HHMI (HHMI)

Zitieren

APA

Pappas, K., Ferrari, M., Smith, P., Nandakumar, S., Khan, Z., Young, S. B., LaClair, J., Russo, M. V., Huang-Hobbs, E., Schultz, N., Abida, W., Karthaus, W., Jasin, M., & L Sawyers, C. (2025). BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function. Proceedings of the National Academy of Sciences, 122(23). https://doi.org/10.1073/pnas.2426743122

Vancouver

Pappas K, Ferrari M, Smith P, Nandakumar S, Khan Z, Young SB, et al. BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function. Proceedings of the National Academy of Sciences. 2025;122(23). doi:10.1073/pnas.2426743122

BibTeX
@article{Pappas2025,
  author = {Pappas, Kyrie and Ferrari, Matteo and Smith, Perianne and Nandakumar, Subhiksha and Khan, Zahra and Young, Serina B and LaClair, Justin and Russo, Marco Vincenzo and Huang-Hobbs, Emmet and Schultz, Nikolaus and Abida, Wassim and Karthaus, Wouter and Jasin, Maria and L Sawyers, Charles},
  title = {BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {23},
  doi = {10.1073/pnas.2426743122}
}
Kostenlos starten →